Literature DB >> 17924575

Multiple sclerosis and Alzheimer's disease.

Assunta Dal Bianco1, Monika Bradl, Josa Frischer, Alexandra Kutzelnigg, Kurt Jellinger, Hans Lassmann.   

Abstract

OBJECTIVE: Chronic inflammation with microglia activation is thought to play a major role in the formation or clearance of Alzheimer's disease (AD) lesions, as well as in the induction of demyelination in multiple sclerosis (MS). In MS, the cortex is severely affected by chronic, long-lasting inflammation, microglia activation, and demyelination. To what extent chronic inflammation in the cortex of MS patients influences the development of AD lesions is so far unresolved.
METHODS: The study was performed on autopsy tissue of 45 MS cases, 9 AD cases, and 15 control subjects. We analyzed lymphocyte and plasma cell infiltration in relation to microglia activation, to the presence of beta-amyloid plaques and (AT8+) neurofibrillary tangles, and to myelin pathology.
RESULTS: Profound microglia activation, determined by a broad spectrum of markers, was found in both MS and AD cortices, and the patterns of microglia activation were closely similar. Microglia activation in MS cortex, in contrast with that in AD and control cortex, correlated with lymphocyte and plasma-cell infiltrates in the meninges. MS cases older than 64 years experienced development of AD pathology in comparable incidence as seen in the course of normal aging. The density of beta-amyloid plaques and neurofibrillary tangles did not differ between demyelinated and nondemyelinated cortical areas.
CONCLUSIONS: Our data suggest that microglia activation in the MS cortex alone has little or no influence on the development of cortical AD pathology.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17924575     DOI: 10.1002/ana.21240

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  47 in total

Review 1.  Oligodendrocyte-microglia cross-talk in the central nervous system.

Authors:  Laura Peferoen; Markus Kipp; Paul van der Valk; Johannes M van Noort; Sandra Amor
Journal:  Immunology       Date:  2014-03       Impact factor: 7.397

Review 2.  Multiple sclerosis in the elderly patient.

Authors:  Amer Awad; Olaf Stüve
Journal:  Drugs Aging       Date:  2010-04-01       Impact factor: 3.923

Review 3.  Mechanisms of neurodegeneration shared between multiple sclerosis and Alzheimer's disease.

Authors:  Hans Lassmann
Journal:  J Neural Transm (Vienna)       Date:  2011-03-05       Impact factor: 3.575

Review 4.  Cortical lesions in multiple sclerosis.

Authors:  Massimiliano Calabrese; Massimo Filippi; Paolo Gallo
Journal:  Nat Rev Neurol       Date:  2010-07-13       Impact factor: 42.937

5.  Prominence of central sphingosine-1-phosphate receptor-1 in attenuating aβ-induced injury by fingolimod.

Authors:  Masoumeh Asle-Rousta; Zeynab Kolahdooz; Leila Dargahi; Abolhassan Ahmadiani; Sanaz Nasoohi
Journal:  J Mol Neurosci       Date:  2014-09-20       Impact factor: 3.444

Review 6.  Microglia and brain macrophages in the molecular age: from origin to neuropsychiatric disease.

Authors:  Marco Prinz; Josef Priller
Journal:  Nat Rev Neurosci       Date:  2014-04-09       Impact factor: 34.870

7.  Alzheimer's Disease: Fatty Acids We Eat may be Linked to a Specific Protection via Low-dose Aspirin.

Authors:  Massimo F L Pomponi; Giovanni Gambassi; Massimiliano Pomponi; Carlo Masullo
Journal:  Aging Dis       Date:  2010-07-12       Impact factor: 6.745

Review 8.  Grey matter lesions in MS: from histology to clinical implications.

Authors:  Massimiliano Calabrese; Alice Favaretto; Valeria Martini; Paolo Gallo
Journal:  Prion       Date:  2012-10-23       Impact factor: 3.931

Review 9.  The pathological spectrum of CNS inflammatory demyelinating diseases.

Authors:  Wei Hu; Claudia F Lucchinetti
Journal:  Semin Immunopathol       Date:  2009-09-25       Impact factor: 9.623

Review 10.  Synaptic plasticity in multiple sclerosis and in experimental autoimmune encephalomyelitis.

Authors:  Robert Nisticò; Francesco Mori; Marco Feligioni; Ferdinando Nicoletti; Diego Centonze
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2013-12-02       Impact factor: 6.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.